Form 4: Ikena Oncology CEO Receives Stock Grant
Insider Transaction (Form 4)
Kristin Yarema, Chief Executive Officer and a Director of Ikena Oncology, Inc., reported multiple transactions in common stock on August 14, 2026.
Summary
- Grant/award: acquired 254,800 Common Stock on August 14, 2026; holds 493,705 after (Direct).
- Grant/award: acquired 137,200 Employee Stock Option (right to buy) on August 14, 2026; holds 137,200 after (Direct).
- Grant/award: acquired 250,000 Employee Stock Option (Right to Buy) on August 14, 2026; holds 250,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kristin Yarema — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-14 | Grant/award | Common Stock | 254,800 | — | — | 493,705 |
| 2026-08-14 | Grant/award | Employee Stock Option (right to buy) | 137,200 | — | — | 137,200 |
| 2026-08-14 | Grant/award | Employee Stock Option (Right to Buy) | 250,000 | — | — | 250,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Grant/award (254,800 shares) |
| 2026-08-14 | Grant/award (137,200 shares) |
| 2026-08-14 | Grant/award (250,000 shares) |
Keywords
insider transaction, Form 4, IMA, ImageneBio, Inc., neutral, Kristin Yarema
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.